Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl- 1,4-benzoquinone (RH1)

Molecular Pharmacology

Volumn 74, Issue 6, 2008, Pages 1657-1665

  Yan, Chao ^a,b   Kepa, Jadwiga K ^a,b   Siegel, David ^a,b   Stratford, Ian J ^a,b   Ross, David ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; ANTINEOPLASTIC AGENT; CYTOCHROME B5 REDUCTASE; CYTOCHROME P450 REDUCTASE; DIHYDRONICOTINAMIDE RIBOSIDE: QUINONE OXIDOREDUCTASE 2; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE:QUINONE OXIDOREDUCTASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVATION; DRUG METABOLISM; ENZYMATIC ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; CELL LINE, TUMOR; CYTOCHROMES B5; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDOREDUCTASES; QUINONE REDUCTASES; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

EID: 57349135857     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.050401     Document Type: Article

References (44)

1. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, and Drewes G (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035-1044.
2. Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, et al. (1998) Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem 41:4755-4766.
3. Beckman JS, Parks DA, Pearson JD, Marshall PA, and Freeman BA (1989) A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Radic Biol Med 6:607-615.
4. Begleiter A, Leith MK, Patel D, and Hasinoff BB (2007) Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol 60:713-723.
5. Bligh HF, Bartoszek A, Robson CN, Hickson ID, Kasper CB, Beggs JD, and Wolf CR (1990) Activation of mitomycin C by NADPH: cytochrome P-450 reductase. Cancer Res 50:7789-7792.
6. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, and Zhang Z (2004) Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43: 11417-11426.
7. Cresteil T and Jaiswal AK (1991) High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42:1021-1027.
8. Cummings J, Ritchie A, Butler J, Ward TH, and Langdon S (2003) Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts. Anticancer Res 23:3979-3983.
9. Cummings J, Spanswick VJ, Tomasz M, and Smyth JF (1998) Enzymology of mitomycin C metabolic activation in tumour tissue. Biochem Pharmacol 56:405-414.
10. Danson S, Ranson M, Denneny O, Cummings J, and Ward TH (2007) Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Cancer Chemother Pharmacol 60:851-861.
11. Dehn DL, Inayat-Hussain SH, and Ross D (2005) RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis. J Pharmacol Exp Ther 313:771-779.
12. Dehn DL, Winski SL, and Ross D (2004) Development of a new isogenic cellxenograft system for evaluation of NAD(H):quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. Clin Cancer Res 10:3147-3155.
13. Ernster L (1967) DT-diaphorase. Methods Enzymol 10:309-317.
14. Fisher GR, Donis J, and Gutierrez PL (1992) Reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells. II. Enhancement of the alkylating activity of AZQ by NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase). Biochem Pharmacol 44:1625-1635.
15. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88:259-269.
16. Friedlos F, Jarman M, Davies LC, Boland MP, and Knox RJ (1992) Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochem Pharmacol 44:25-31.
17. Hasinoff BB and Begleiter A (2006) The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells. Free Radic Res 40:974-978.
18. 5 reductase. Cancer Res 53:4907-4912.
19. Jamieson D, Tung AT, Knox RJ, and Boddy AV (2006) Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. Br J Cancer 95:1229-1233.
20. Kim JY, Patterson AV, Stratford IJ, and Hendry JH (2004) The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines. Anticancer Drugs 15:71-77.
21. Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, and Burke PJ (2000) Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 60:4179-4186.
22. Loadman PM, Phillips RM, Lim LE, and Bibby MC (2000) Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3- (hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. Biochem Pharmacol 59:831-837.
23. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Lusthof KJ, de Mol NJ, Richter W, Janssen LH, Butler J, Hoey BM, Verboom W, and Reinhoudt DN (1992) Redox cycling of potential antitumor aziridinyl quinones. Free Radic Biol Med 13:599-608.
25. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, and Harrison SD (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52:4752-4757.
26. Mihara K and Sato R (1978) Detergent-solubilized NADH-cytochrome b5 reductase. Methods Enzymol 52:102-108.
27. Mikami K, Naito M, Ishiguro T, Yano H, Tomida A, Yamada T, Tanaka N, Shirakusa T, and Tsuruo T (1998) Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Jpn J Cancer Res 89:910-915.
28. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
29. Pan SS, Andrews PA, Glover CJ, and Bachur NR (1984) Reductive activation of mitomycin C metabolites catalyzed by NADPH-cytochrome P450 reductase and xanthine oxidase. J Biol Chem 259:959-966.
30. Powis G (1989) Free radical formation by antitumor quinones. Free Radic Biol Med 6:63-101.
31. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110:4055-4063.
32. Saunders MP, Jaffar M, Patterson AV, Nolan J, Naylor MA, Phillips RM, Harris AL, and Stratford IJ (2000) The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 59:993-996.
33. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, and Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 59:263-268.
34. Stirpe F and Della Corte E (1969) The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O). J Biol Chem 244:3855-3863.
35. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, and Sasaki YF (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
36. Tudor G, Alley M, Nelson CM, Huang R, Covell DG, Gutierrez P, and Sausville EA (2005) Cytotoxicity of RH1:NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction. Anticancer Drugs 16:381-391.
37. Vermilion JL and Coon MJ (1978) Purified liver microsomal NADPH-cytochrome P-450 reductase. Spectral characterization of oxidation-reduction states. J Biol Chem 253:2694-2704.
38. Vichai V and Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116.
39. Walton MI, Smith PJ, and Workman P (1991) The role of NAD-(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. Cancer Commun 3:199-206.
40. Ward TH, Butler J, Shahbakhti H, and Richards JT (1997) Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. Biochem Pharmacol 53:1115-1121.
41. Ward TH, Coe N, Hargreaves R, Bulter J, and McGown AT (2000) Crosslinking studies on the novel bioreductive anti-cancer drug RH1. Clin Cancer Res 6 Suppl: 4527s.
42. Winski SL, Hargreaves RH, Butler J, and Ross D (1998) A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 4:3083-3088.
43. Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, and Ross D (2001) Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 61:1509-1516.
44. Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, Deng PS, and Chen S (1997) Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 347:221-228.